| Lloyd H Stegemann, MD | |
|
5826 Esplanade Dr, Suite 102, Corpus Christi, TX 78414-4173 | |
| (361) 500-2898 | |
| Not Available |
| Full Name | Lloyd H Stegemann |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 26 Years |
| Location | 5826 Esplanade Dr, Corpus Christi, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134117450 | NPI | - | NPPES |
| 158332001 | Medicaid | TX | |
| 8F9151 | Other | TX | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | L5917 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Corpus Christi Medical Center,the | Corpus christi, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Better Weigh Center Pllc | 4183887151 | 3 |
News Archive
The drug aclidinium bromide has been approved since October 2012 for widening the narrowed airways of adults with chronic-obstructive pulmonary disease (COPD). The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit of the drug pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG).
More than 30 million Americans have diabetes, with the vast majority having Type 2 disease. Characterized by insulin resistance and persistently high blood sugar levels, poorly controlled Type 2 diabetes has a host of well-recognized complications: compared with the general population, a greatly increased risk of kidney disease, vision loss, heart attacks and strokes, and lower limb amputations.
Older veterans who experienced traumatic brain injury showed a more than two-fold increase in the risk of developing dementia, according to new research presented today at the Alzheimer's Association® International Conference 2011 (AAIC 2011) in Paris.
In a report of a proof-of-principle study of patients with colon and other cancers for whom standard therapies failed, researchers at the Johns Hopkins Kimmel Cancer Center say that mistakes in so-called mismatch repair genes, first identified by Johns Hopkins and other scientists two decades ago, may accurately predict who will respond to certain immunotherapy drugs known as PD-1 inhibitors. Such drugs aim to disarm systems developed by cancer cells to evade detection and destruction by immune system cells.
› Verified 8 days ago
| Entity Name | Better Weigh Center Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922372804 PECOS PAC ID: 4183887151 Enrollment ID: O20120601000020 |
News Archive
The drug aclidinium bromide has been approved since October 2012 for widening the narrowed airways of adults with chronic-obstructive pulmonary disease (COPD). The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit of the drug pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG).
More than 30 million Americans have diabetes, with the vast majority having Type 2 disease. Characterized by insulin resistance and persistently high blood sugar levels, poorly controlled Type 2 diabetes has a host of well-recognized complications: compared with the general population, a greatly increased risk of kidney disease, vision loss, heart attacks and strokes, and lower limb amputations.
Older veterans who experienced traumatic brain injury showed a more than two-fold increase in the risk of developing dementia, according to new research presented today at the Alzheimer's Association® International Conference 2011 (AAIC 2011) in Paris.
In a report of a proof-of-principle study of patients with colon and other cancers for whom standard therapies failed, researchers at the Johns Hopkins Kimmel Cancer Center say that mistakes in so-called mismatch repair genes, first identified by Johns Hopkins and other scientists two decades ago, may accurately predict who will respond to certain immunotherapy drugs known as PD-1 inhibitors. Such drugs aim to disarm systems developed by cancer cells to evade detection and destruction by immune system cells.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lloyd H Stegemann, MD 5826 Esplanade Dr, Suite 102, Corpus Christi, TX 78414-4173 Ph: (361) 500-2898 | Lloyd H Stegemann, MD 5826 Esplanade Dr, Suite 102, Corpus Christi, TX 78414-4173 Ph: (361) 500-2898 |
News Archive
The drug aclidinium bromide has been approved since October 2012 for widening the narrowed airways of adults with chronic-obstructive pulmonary disease (COPD). The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit of the drug pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG).
More than 30 million Americans have diabetes, with the vast majority having Type 2 disease. Characterized by insulin resistance and persistently high blood sugar levels, poorly controlled Type 2 diabetes has a host of well-recognized complications: compared with the general population, a greatly increased risk of kidney disease, vision loss, heart attacks and strokes, and lower limb amputations.
Older veterans who experienced traumatic brain injury showed a more than two-fold increase in the risk of developing dementia, according to new research presented today at the Alzheimer's Association® International Conference 2011 (AAIC 2011) in Paris.
In a report of a proof-of-principle study of patients with colon and other cancers for whom standard therapies failed, researchers at the Johns Hopkins Kimmel Cancer Center say that mistakes in so-called mismatch repair genes, first identified by Johns Hopkins and other scientists two decades ago, may accurately predict who will respond to certain immunotherapy drugs known as PD-1 inhibitors. Such drugs aim to disarm systems developed by cancer cells to evade detection and destruction by immune system cells.
› Verified 8 days ago
Dr. David Kerek, DO Surgery Medicare: Not Enrolled in Medicare Practice Location: 2606 Hospital Blvd, Corpus Christi, TX 78405 Phone: 361-985-1221 Fax: 361-985-1295 | |
Dr. James Mitchell Dye, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 6133 Parkway, Corpus Christi, TX 78414 Phone: 361-881-8333 Fax: 361-881-8753 | |
Mr. Steven J Steele, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 3301 S Alameda St, Ste 304, Corpus Christi, TX 78411 Phone: 361-851-0110 Fax: 361-851-9813 | |
Dr. David Johnson, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 2606 Hospital Blvd, Corpus Christi, TX 78405 Phone: 361-985-1221 Fax: 361-985-1295 | |
Dr. Thomas Michael Townsend, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 6133 Parkway, Corpus Christi, TX 78414 Phone: 361-881-8333 Fax: 361-881-8753 | |
Dr. Michael James Ewing, M.D, Surgery Medicare: Accepting Medicare Assignments Practice Location: 6133 Parkway Dr, Corpus Christi, TX 78414 Phone: 361-881-8333 |